ReviewSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025
[Advances in Multi-omics Analysis of Cervical Cancer].
Review in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer (CC), a common malignant tumor afflicting women, poses serious threats to their health. Therefore, it is critical to develop a thorough understanding of the molecular mechanisms underlying the pathogenesis of CC, and to identify new therapeutic targets and methods for early diagnosis. The multi-omics research in tumors, involving proteomics, transcriptomics, genomics, microbiomics, and metabolomic, offers valuable insights. The multi-omics analysis of biological samples from patients with cervical intraepithelial neoplasia (CIN) and CC can help clarify the pathways involved in the pathogenesis and development of CC. Furthermore, multi-omics studies have identified a number of molecules associated with CC, including actin, lumican, family member with sequence similarity 83 (FAM83A), cadherin EGF-LAG seven-pass G-type receptor 3 (CELSR3), and 5,10-methylenetetrahydrofolate reductase (MTHFR), all of which show potential to be used as new biomarkers. These biomarkers will help make early diagnosis, improve the survival and prognosis of CC patients, and ultimately reduce CC incidence and mortality. This review synthesizes current advances in multi-omics research on cervical cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.